Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Morning Wrap: Wall Street Returns to the Offensive as Palantir Fuels AI Optimism
SpaceX Preview: It's Time to See How Much of Its Valuation Is Based on Business and How Much on Promise
Economic Calendar: What Could Move the Market This Week? (03.08.2026)
Market Wrap: European equities at 3-week highs! Apple dips in US premarket!